An Intermediate Size Expanded Access Protocol of Elamipretide
An Intermediate Size Expanded Access Protocol of Elamipretide for Subcutaneous Injection in Patients With Genetically Confirmed Rare Diseases With Known Mitochondrial Dysfunction
Sponsor: Stealth BioTherapeutics Inc.
This observational or N/A phase trial investigates Barth Syndrome and Mitochondrial Diseases and is currently ongoing. Stealth BioTherapeutics Inc. leads this study, which shows 9 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
9 versions recorded-
Mar 2025 — Present [monthly]
Available
-
Sep 2024 — Mar 2025 [monthly]
Available
-
Aug 2024 — Sep 2024 [monthly]
Available
-
Jul 2024 — Aug 2024 [monthly]
Available
-
Apr 2023 — Jul 2024 [monthly]
Available
▶ Show 4 earlier versions
-
Dec 2021 — Apr 2023 [monthly]
Available
-
Nov 2021 — Dec 2021 [monthly]
Available
-
Feb 2021 — Nov 2021 [monthly]
Available
-
Jan 2021 — Feb 2021 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stealth BioTherapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.